SeaStar Medical (ICU) Q2 FY26 earnings call

SeaStar Medical is advancing its first-in-class immunomodulatory therapy, QUELIMMUNE, with strong adoption in the pediatric AKI market and steady progress in its pivotal adult AKI trial. The company is strategically expanding its commercial footprint while navigating increased R&D costs associated with trial acceleration, aiming for a late 2027 PMA submission for the adult indication.